

Review

Roles of the Hedgehog Signaling Pathway in Skin Development, Homeostasis and Cancer

Yoshinori Abe¹ and Nobuyuki Tanaka^{1,*}

¹ Department of Molecular Oncology, Institute for Advanced Medical Sciences, Nippon Medical School, 1-396 Kosugi-cho, Nakahara-ku, Kawasaki 211-8533, Japan; yoshiabe@nms.ac.jp (Y.A.), nobuta@nms.ac.jp (N.T.)

* Correspondence: nobuta@nms.ac.jp; Tel.: +81-44-733-1860

Abstract: The epidermis is the outermost layer of skin and provides a protective barrier against environmental insults. It is a rapidly renewing tissue undergoing constant regeneration, maintained by several types of stem cells. Hedgehog (HH) ligands activate one of the fundamental signaling pathways that contribute to epidermal development, homeostasis and repair. The HH pathway interacts with other signal transduction pathways such as those activated by Wnt and bone morphogenetic protein. Furthermore, aberrant activation of HH signaling is associated with various tumors, including basal cell carcinoma. Therefore, an understanding of the regulatory mechanisms of the HH signaling pathway is important to elucidate fundamental mechanisms underlying both organogenesis and carcinogenesis. In this review, we discuss the role of the HH signaling pathway in skin development, homeostasis and basal cell carcinoma formation, providing an update of current knowledge in this field.

Keywords: Hedgehog signaling; skin; epidermis; hair follicle; development; homeostasis; basal cell carcinoma; signaling crosstalk

1. Introduction

Although the thickness of the skin is as little as 2 mm on average, it is a complex stratified organ consisting of an outer epidermis and appendages (for example, hair follicles, sebaceous glands and sweat glands) separated from the underlying dermis by a basement membrane. It is the largest organ in the human body, by area and weight. Skin is the primary barrier that protects the body from major environmental stresses such as dehydration, scratches, wounds and microbial infection [1]. To repair damaged tissue and replace old cells, different stem cell pools resident in the skin contribute to the maintenance and repair of the various epidermal tissues, including interfollicular epidermis, hair follicles and sebaceous glands [2,3]. The stem cells residing in the epidermis are maintained by various signaling pathways such as those activated by Wnt, transforming growth factor β (TGF- β), Notch and Hedgehog (HH) [3]. These signaling pathways also have important roles in embryonic skin development [4]. However, the dysregulation of signaling pathways related to skin development and homeostasis induces epigenetic reprogramming of skin cells, resulting in cancer development. In particular, aberrant activation of HH signaling is the major cause of basal cell carcinoma (BCC) [5]. In this review, we provide a current understanding of the role of the HH signaling pathway in embryonic skin development, skin homeostasis and skin cancer.

2. The HH Signaling Pathway

The HH pathway is one of the most important signal transduction pathways in tissue development, homeostasis and repair. It regulates the morphogenesis of various organs during embryogenesis [6]. We show a schematic diagram of the HH signaling pathway in Figure 1. However, HH signaling is complex, and several comprehensive reviews have been published describing the molecular mechanisms in detail [7–10]. In the canonical pathway, HH signaling is

initiated by one of three spatiotemporally confined ligands: Sonic Hedgehog (SHH), Indian Hedgehog (IHH) and Desert Hedgehog (DHH). HH ligands control numerous developmental outcomes in a concentration- and duration-dependent manner. Each HH ligand has distinct spatial and temporal expression patterns, but all activate HH signaling by binding to Patched (PTCH) 1 or 2, which are 12-pass transmembrane-spanning receptors. PTCH1 is considered to be the primary receptor for HH ligands. In the absence of HH, PTCH1 is localized in primary cilia and constitutively suppresses the activity of Smoothened (SMO), a 7-pass transmembrane-spanning protein that is a member of the G-protein-coupled receptor superfamily [11]. Suppressor of fused (SUFU) is a key negative regulator of the HH signaling pathway [12]. In the absence of HH ligands, SUFU inhibits signaling by sequestration of GLI proteins in the cytoplasm (Figure 1A). In addition to PTCH, other HH-binding cell surface proteins have been identified, such as CAM-related/down-regulated by oncogenes (CDO), brother of Cdo (BOC) and growth-arrest-specific 1 (GAS1) [13,14]. These molecules function as HH coreceptors to facilitate HH signal reception. Following the binding of a HH ligand to PTCH, SMO accumulates at a specialized compartment in the primary cilium called the EvC zone, mediated by the Ellis van Creveld Syndrome (EVC)–EVC2 complex [15,16]. From here, SMO transmits signals that activate GLI (Figure 1B) [17,18].




Figure 1. The Hedgehog signaling pathway. (A) In the absence of Hedgehog (HH) ligand, Patched (PTCH) blocks ciliary localization of Smoothened (SMO), and a repressor form of GLI (mainly GLI3R) suppresses the induction of GLI target genes. (B) Signaling is activated in the presence of HH ligand. The binding of HH ligand to PTCH prevents PTCH inhibition of SMO, and SMO then interacts with the Ellis van Creveld Syndrome (EVC)–EVC2 complex and translocates into primary cilia to be fully activated. SMO then activates GLI family transcription factors, mainly GLI2. GLI2 upregulates expression of GLI1 as well as GLI target genes. GLI1 is also activated downstream of SMO. Activated GLI2 (GLI2A) and GLI1 further upregulate the expression of various GLI target genes. This figure is adapted from a my previous work [19].

Graded levels of HH signaling trigger the expression of different sets of response genes, depending on the ratio of Gli activator (GLI-A) to repressor (GLI-R) forms. In vertebrates, the GLI family consists of three proteins, GLI1, GLI2 and GLI3 [9]. All GLI proteins contain an activator domain at their C-terminus; GLI2 and GLI3 also have an N-terminal repressor domain [20]. Studies in mutant mice suggest that GLI2 is the major activator of HH signaling [21], whereas GLI3 is the major repressor [22,23]. GLI1 most likely serves as a signal amplifier downstream of GLI2 [21,24]. When HH signaling is activated, SUFU–GLI2 complexes dissociate and GLI2 is activated [25]. *Gli2*

knockout mice die at birth, whereas *Gli1* knockout mice show normal development, unless one copy of *Gli2* is also defective [26]. Interestingly, experiments in mutant mice further suggest that *Gli2* can rescue *Gli1* protein function, whereas *Gli1* knock-in into the *Gli2* allele can rescue the *Gli2*-null phenotype [27].

Constitutive activation of HH signaling has been observed in many cancers [28] and promotes cancer cell proliferation, metastasis and cancer stem cell maintenance. For example, somatic mutations of *PTCH1* and *SMO* have been identified in patients with BCC and medulloblastoma [29–32]. Other mutations in genes encoding HH pathway components have been reported, including *SUFU* mutations in BCC and medulloblastoma [33]. Furthermore, multiple mechanisms of HH pathway activation in cancer have been proposed, and reviewed in detail elsewhere [10,34,35].

HH signaling exhibits crosstalk with other signaling pathways, including Wnt [36–39], TGF- β [40], epidermal growth factor receptor (EGFR) [41], rat sarcoma viral oncogene homolog GTPase (RAS)–extracellular signal-regulated kinase (ERK) [42,43], phosphatidylinositol 3-kinase (PI3K)–Akt–mechanistic target of rapamycin (mTOR) [44] and Notch [45]. Interestingly, the crosstalk between HH signaling and other pathways seem to be different between developmental, homeostatic and carcinogenic processes.

3. Overview of Epidermal and Hair Follicle Development

3.1. Development of the Epidermis

During embryonic development, the epidermis is derived from the ectoderm. In the mouse, after gastrulation, the embryo surface consists of a single layer of neuroectoderm, which will form the nervous system and skin epithelium from embryonic day 9.5 (E9.5) to E12.5. Mesenchymal cells from the underlying layer transmit signals that instruct the stratification of the epidermis and dictate the positioning of downgrowths that mark the initiation of hair follicle morphogenesis [1]. In alliance with the mesenchyme, the inner-most, or basal layer of the stratifying epidermis produces and organizes an underlying basement membrane that is rich in extracellular matrix proteins and growth factors. The epidermis adheres to this basement membrane, which serves not only as a growth-promoting platform but also as a physical boundary between the epithelium and the dermis [46]. During the initial steps of stratification (E12.5–E15.5), cell proliferation is almost completely confined to the basal layer, and these cells differentiate immediately. In this period, the single layer of epidermal cells is covered by a transient protective layer called the periderm. Although there is regional variation, the stratification program is largely complete around E17.5 [47].

3.2. Hair Follicle Development

The development of hair follicles is intrinsically related to the stratification of the embryonic epidermis. Hair follicle development is the result of epithelial–mesenchymal interactions. Although hair follicle development occurs in eight morphologically distinct stages, it can more simply be divided into three phases: induction, organogenesis and cytodifferentiation [48]. In the induction phase, which is the initiation of hair follicle development (E13), signaling crosstalk between the epidermis and dermis is induced, and epidermal keratinocytes form clusters that become enlarged and elongated to form hair placodes (E14). Hair follicle development then enters the organogenesis phase. A cluster of specialized fibroblasts, the precursors of the dermal papilla, is formed just under the placode, and the signaling crosstalk between these specialized fibroblasts and the epithelial placode leads to cell proliferation in both structures. The enhanced cell proliferation leads to a downward growth of the epidermal component, shaping the dermal papilla. The resulting structure, called the hair germ, is typically observed at E15.5. Keratinocyte downgrowth continues, whereby the most proximally located keratinocytes begin to wrap around the dermal papilla (E16.5–E17.5). As follicles enter the cytodifferentiation phase, the inner root sheath is formed, triggering the terminal differentiation of keratinocytes above the dermal papilla to generate the hair shaft.

Simultaneously, the outer root sheath starts to form a cylinder around the inner root sheath to create a bulbous peg structure (E18.5). Additional appendages such as sebaceous glands and touch domes also develop during this phase. These timelines are summarized in Figure 2. For a more detailed discussion of hair follicle development, please refer to several published reviews [2,4,49].




Figure 2. At the beginning of hair follicle development, gradients of activators and inhibitors generate a well-circumscribed inductive field (E13). These gradients induce epithelial and dermal cell proliferation to develop a placode and a dermal papilla (E14). The dermal papilla sends growth signals back to the epithelial cells to form the hair follicle (E15.5–E17.5). In the cytodifferentiation phase, epithelial cells differentiate into inner and outer root sheath, which generates the hair shaft. In addition, melanocytes and hematopoietic cells migrate into the hair follicle, and touch domes and sebaceous glands are formed.

4. The Roles of HH Signaling in Hair Follicle Development

In mouse skin at E15.5, at the beginning of the organogenesis phase of hair follicle development, *Ptch1*, *Smo*, *Gli1* and *Gli2* are expressed in both the epithelial and dermal components of the early hair follicle, although higher levels of *Ptch1* and *Gli1* are observed in the follicular dermal mesenchyme. In contrast, *Ptch2* expression is restricted to epithelial cells of the hair bud where it is co-expressed with *Shh* [47,50]. Therefore, the HH signaling pathway functions in both the epithelium and the mesenchyme. In mice lacking *Shh*, hair follicle formation is initiated and specialized fibroblasts are condensed, indicating that the initial events of hair follicle development are independent of HH signaling. However, in the hair follicle maturation phase, the loss of *Shh* selectively reduces keratinocyte proliferation in the developing follicle epithelium, so that the downgrowth of epithelial cells fails. Therefore, the number of hair follicles is reduced in *Shh*^{-/-} mice. Thus, HH signaling is necessary for the transition from the induction to the organogenesis phase, and for the downgrowth of epithelial cells after the induction phase. Furthermore, the maturation of the dermal papilla also depends on HH signaling, since *Shh*^{-/-} mice have smaller dermal papillae [50,51]. It is believed that GLI2 is the primary transducer of HH signaling, whereas GLI1, the expression of which is transcriptionally regulated by GLI2, plays a secondary role in potentiating the HH response [9]. Mill *et al.* demonstrated that hair follicle maturation fails in *Gli2*^{-/-} skin because of

suppressed epithelial cell proliferation, similar to *Shh*^{-/-} skin [52]. Development of the dermal papilla is also severely affected by the failure to respond to SHH in *Gli2*^{-/-} skin. In addition, *Shh*^{-/-} as well as *Gli2*^{-/-} skin fails to induce Gli1. Together, these results show that the SHH–GLI2 axis is required for the proliferation and subsequent downgrowth of the follicular epithelium, and for the maturation of the dermal papilla.

As described above, the expression of *Ptch1*, *Smo*, *Gli1* and *Gli2* is seen in the dermal papilla [50], indicating that HH signaling also functions in dermal cells. RNAi-mediated SMO knockdown in dermal cells results in the loss of the dermal papilla precursor, the dermal cell condensate, and in hair follicle arrest at the organogenesis phase, similar to *Shh*^{-/-} skin. However, HH signaling in dermal cells does not affect cell survival or epithelial proliferation. Rather, dermal HH signaling regulates the expression of a subset of dermal papilla-specific signature genes. These results suggest that dermal HH signaling regulates genes required to maintain the maturation of the papilla [53]. Sex determining region Y-box 2 (SOX2) is expressed only in the dermal papilla and determines hair follicle type [54,55]. Recently, Driskel *et al.* demonstrated that dermal papilla cells are heterogeneous and SOX2⁺/CD133⁺ dermal papilla cells are associated with guard, awl and auchene hair follicle formation whereas SOX2⁻/CD133⁺ dermal papilla cells are involved in the formation of zigzag hair follicles. Moreover, they demonstrated the HH signaling pathway is activated in SOX2⁻/CD133⁺ dermal papilla cells, suggesting that HH signaling regulates hair type fate determination through the maintenance of dermal papilla cell heterogeneity [55]. The roles of the HH signaling pathway in hair follicle development are summarized in Figure 3.




Figure 3. The roles of the HH signaling pathway in embryonic hair follicle development. In epidermal cells, HH signaling is involved in germ cell and follicular cell proliferation. HH signaling is also involved in the maturation of the dermal papilla, as well as dermal papilla heterogeneity. Furthermore, HH signaling is essential for Merkel cell proliferation and touch dome development.

On the other hand, negative regulators of HH signaling are also important for hair follicle development. PTCH1 and 2 are known to be negative regulators of HH signaling, and *Ptch1* is a GLI target gene [47,56]. Basal cell-specific *Ptch1*-null skin exhibits hyperplasia and skin neoplasia formation, although *Ptch2*-null skin is undistinguishable from wild-type skin with respect to embryonic hair follicle development [57,58]. However, the skin of both basal cell-specific *Ptch1*-null and *Ptch2*-null mice exhibits excessive proliferation of epithelial cells, suggesting that epidermal stem and progenitor cells enter a hyperproliferative state. In addition, progenitor cells fail to differentiate, resulting in the loss of epidermal lineage specification. Therefore, PTCH1- and

2-mediated HH signaling suppression is important for regulating epidermal differentiation [59]. Another study reported that increased numbers of immature hair follicles in the induction phase are seen in *Shh*^{-/-}/*Gli3*^{-/-} skin, in which the repressor form of GLI3 (GLI3R), another negative regulator of HH signaling, is lost. Furthermore, keratinocyte differentiation fails in *Shh*^{-/-}/*Gli3*^{-/-} skin, resulting in the failure of hair follicle maturation [60]. Recently, Adolphe *et al.* discovered that there is a HH signaling gradient along the proximodistal axis of developing hair follicles [61]. At E17.5, the peak of HH signaling activity is in follicular cells, which are a source of SHH, and HH signaling is endogenously low in basal cells. This HH signaling gradient is established by PTCH1 and PTCH2. These results suggest that HH signaling has the capacity for progenitor cell maintenance, and the intensity of HH signaling is important for both epithelial and mesenchymal cell fate determination during hair follicle development.

5. Signaling Crosstalk between HH and Other Pathways in Hair Follicle Development

The hair follicle develops as a result of complex reciprocal signaling between epithelial and mesenchymal cells. Various signaling pathways such as those activated by Wnt and bone morphogenetic protein (BMP) are involved in hair follicle development, and exhibit signaling crosstalk with the HH pathway. In this section, we discuss the crosstalk between HH and other signaling pathways in hair follicle development.

5.1. Wnt signaling

The Wnt signaling pathway has been implicated in many developmental processes [62]. Canonical Wnt signaling is mediated by a transcriptionally active complex between stabilized β -catenin and members of the T-cell factor (TCF)/Lymphoid enhancer-binding factor 1 (LEF-1) family of DNA-binding proteins [63]. One of the first, essential events required to form a follicle placode is the activation of Wnt signaling in the epidermis. Wnt signaling also transmits subsequent signals for hair follicle development and patterning. Wnt ligands are expressed in interfollicular epidermis as well as the hair follicle during all stages of follicle development, suggesting that Wnt signaling is a master regulator of follicle development [36,64,65].

The Wnt and HH signaling pathways are often associated. During hair follicle development in mouse embryos, the canonical Wnt signaling pathway is upstream of HH signaling, since β -catenin activation induces *Shh* expression in epidermis during skin development [36,37]. On the other hand, Reddy *et al.* showed that dermal Wnt5a disappears in *Shh*^{-/-} skin, indicating that Wnt5a is downstream or even a direct target of HH signaling [66]. Therefore, SHH-induced dermal Wnt5a as well as GLI1 expression is important for dermal papilla maturation. Wnt5a suppresses expression of LEF-1, a well-recognized Wnt/ β -catenin signaling target in human dermal papilla cells, indicating suppression of canonical Wnt signaling [67]. Therefore, the HH-Wnt5a axis terminates cell proliferation and induces differentiation to promote mature hair follicle formation. Since PTCH1 and 2, repressors of HH signaling, are also involved in the induction of cell differentiation, cooperation between Wnt5a and negative regulators of HH signaling may be important for cell differentiation during hair follicle development.

5.2. BMP signaling

BMPs are members of TGF- β family. BMP signaling has been suggested to regulate hair follicle induction and the patterning of follicles within the skin by repressing the placode fate [68,69]. Suzuki *et al.* demonstrated crosstalk among the Wnt, HH and BMP signaling pathways during hair follicle development [37]. Expression of constitutively active β -catenin induces aberrant keratinocyte proliferation and differentiation in mouse skin during hair follicle development; the aberrant cell differentiation is suppressed by BMP signaling inhibition, and the aberrant cell proliferation is suppressed by HH signaling inhibition. These results demonstrate that Wnt/ β -catenin signaling relayed through HH and BMP signals is the principal regulatory mechanism underlying changes in hair follicle cell fate. Furthermore, activation of the HH signaling pathway induces expression of

BMP2 in the organogenesis phase of hair follicle development. A possible mechanism for the regulation of hair follicle development involves cell fate being controlled by the difference in diffusion area between promoters such as SHH and suppressors such as BMP [70,71]. Therefore, the presence of signaling crosstalk involving the Wnt, HH and BMP pathways would regulate the diffusion areas of HH and BMP ligands to determine hair follicle cell fate.

The HH signaling pathway also affects dermal cells during hair follicle development. Noggin is known as an antagonist of BMPs, and Noggin signaling is a dermal papilla-specific pathway. In *noggin*^{-/-} mice, hair follicles arrest at the placode formation stage of embryonic development [68,72]. Oro *et al.* showed that interaction between HH signaling and Noggin regulates dermal papilla maturation during hair follicle development [53]. Dermal cell-specific RNAi-mediated SMO knockdown does not affect dermal cell proliferation in mice. However, dermal cell condensation following placode formation fails in these mice. These authors found that dermal HH signaling induces dermal papilla signature genes such as *Sox2* [54,55], *Sox18* [73,74] and *noggin*. Among these genes, *noggin* partially rescues dermal SMO knockdown-associated hair regeneration defects by increasing epithelial *Shh* expression. These results suggest that dermal HH signaling regulates specific dermal papilla gene expression signatures to maintain dermal papilla maturation while maintaining a reciprocal HH–Noggin signaling loop to drive embryonic hair follicle development.

5.3. The *EdaA1–EdaR–NF-κB* axis

Ectodysplasin A1 (EdaA1) and ectodysplasin receptor (EdaR) respectively belong to the tumor necrosis factor (TNF) multigene family of ligands and receptors, and are able to activate the nuclear factor-κB (NF-κB) and Jun amino-terminal kinase (JNK)/activator protein 1 (AP1) pathway *in vitro* [75–78]. The EdaA1–EdaR pathway is activated at placode formation only in primary guard hair follicles. It has been reported that the EdaA1–EdaR–NF-κB axis is involved in placode formation, since NF-κB is directly activated by EdaA1–EdaR signaling via the IκB kinase (IKK) complex. Schmidt-Ullrich *et al.* demonstrated an interaction between the EdaA1–EdaR–NF-κB axis and the HH signaling pathway [79]. They found that EdaA1–EdaR signaling-mediated NF-κB activation is essential for the induction of SHH expression and subsequent placode downgrowth. However, NF-κB induces cyclin D1 indirectly, suggesting direct induction by HH (or Wnt) signaling. These results taken together suggest that, during hair follicle development, NF-κB transmits EdaA1–EdaR signaling to activate the HH signaling pathway via the direct NF-κB-mediated induction of SHH.

6. Epidermal Homeostasis

The adult epidermis consists of several layers, each with its own characteristics. Cells in the basal layer proliferate to provide new cells that replace those shed from the cornified exterior of the tissue [80]. This renewal process is called homeostasis. Epidermal homeostasis requires a balance between keratinocyte proliferation and differentiation [81,82]. In the skin, multiple populations of epidermal stem cells have a crucial role in maintaining tissue homeostasis, providing new cells to replace those that are constantly lost during tissue turnover or following injury [83]. The epidermis is composed of the interfollicular epidermis, hair follicles, sebaceous glands and sweat glands, and each of these tissues has its resident stem cells. The permanent, lower part of the hair follicle, known as the bulge, is one reservoir of stem cells. Bulge stem cells were originally identified as slow cycling cells [84,85]. A large number of markers have been described for these cells. CD34 cell surface glycoprotein [86,87] and Leu-rich repeat-containing G protein-coupled receptor 5 (LGR5) are considered to be markers of bulge stem cells [88,89]. Recent studies have reported that HH signaling is involved in the maintenance of one type of bulge stem cells. We discuss the role of the HH signaling pathway in bulge stem cell maintenance below.

279 7. Roles of the HH Signaling Pathway in Epidermal Homeostasis

280 Treatment of adult mice with an anti-SHH antibody blocks the active phase of the hair growth
281 cycle (anagen) and blocks hair regrowth [90], indicating that SHH is required for the regenerative
282 function of adult bulge stem cells. Conversely, exogenously administered SHH triggers anagen
283 onset in follicles in the resting phase of the hair cycle (telogen), and stimulates hair growth [91].
284 These reports suggest that HH signaling is involved in hair follicle maintenance.

285 In adult skin, stem cells in the hair follicle bulge cyclically regenerate the follicle, whereas a
286 distinct stem cell population maintains the epidermis. In telogen hair follicles, GLI2 and GLI3
287 continue to be broadly expressed in both the follicle and the surrounding dermis. Throughout the
288 hair cycle, GLI1 expression is restricted to two distinct epidermal stem cell domains [92]. One
289 population of GLI1-expressing (GLI1⁺) stem cells co-expresses LGR5 [88,89]. Stem cells expressing
290 both GLI1 and LGR5 (GLI1⁺/LGR5⁺) exhibit greater proliferative properties and are localized to the
291 lower portion of the bulge, close to the telogen hair germ. In this phase of the hair cycle, GLI1⁺/LGR5⁺
292 stem cells only partially overlap with other bulge stem cells markers such as CD34 and keratin 15.
293 However, in anagen hair follicles, GLI1⁺/LGR5⁺ stem cells are localized to the lower part of the outer
294 root sheath of the reforming hair follicle, where they lose expression of bulge stem cell markers [93].
295 This localization change during the hair cycle suggests that GLI1⁺/LGR5⁺ stem cells may be also
296 necessary for hair follicle growth in anagen. Another population of GLI1⁺ stem cells in the dermal
297 papilla is involved in dermal papilla maintenance. These results show that, during anagen, the
298 induction of HH target genes, including *Gli1*, occurs in both epidermal and dermal papilla cells
299 adjacent to SHH-expressing cells, such as those in the follicle matrix.

300 Another population of GLI1⁺ stem cells that does not express LGR5, CD34 or keratin 15 exists in
301 the upper fringe of the bulge. GLI1⁺ upper bulge stem cells are induced by bulge-associated nerve
302 cells releasing SHH. GLI1⁺ stem cells from the upper bulge stably remain in a wounded area of the
303 skin long after it has been repaired [92]. Therefore, upper bulge cells might constitute a long-term
304 reservoir of stem cells poised to contribute to the repair of the interfollicular epidermis in a
305 permanent manner. Interestingly, the HH signaling pathway is essential for the contribution of
306 upper bulge stem cells to wound repair, but not for hair follicle cycling. This emphasizes the
307 relevance of the niche for the function of different populations of hair follicle stem cells [92]. Matrix
308 cells are known to be a source of SHH, and secreted SHH regulates epithelial cell proliferation and
309 dermal papilla maturation. Moreover, SHH governs dermal adipocyte precursors in adult hair
310 cycling. In turn, dermal adipocytes and adipocyte precursors influence hair cycle progression [94–
311 96]. In addition, dermal adipocytes secrete antimicrobial peptides to protect the skin from bacterial
312 infection [97]. The roles of HH signaling pathway in skin homeostasis are summarized in Figure 4.




Figure 4. GLI1-expressing hair follicle stem cells and their roles. The expression of GLI1 and other markers defines molecularly distinct zones in the telogen hair follicle, including regionalization of the bulge into the upper, middle and lower bulge. GLI1-expressing cells in the upper bulge receive a Hedgehog signal from hair follicle-associated nerve cells, and are functionally distinct from cells in the middle bulge, lower bulge and matrix in their ability to become epidermal stem cells during wound repair. The roles of each GLI1⁺ bulge stem cell population are described in orange text on the right.

8. Signaling Crosstalk between HH and Other Signaling pathways in Skin Homeostasis

8.1. Wnt signaling

The Wnt signaling pathway is also important for the maintenance of hair follicles in adult skin. As described above, activation of canonical Wnt signaling induces SHH expression, indicating HH signaling activation during hair follicle development in mouse embryos. Previous studies have demonstrated that the Wnt–HH signaling axis is also essential for maintaining the hair cycle. Epidermal basal cell-specific β -catenin activation in adult mouse skin also induces SHH expression, resulting in HH signaling activation [38,39], and HH signaling is required for β -catenin-mediated hair follicle formation [39].

8.2. The Hippo–YAP signaling pathway

The Hippo signaling pathway is a master regulator of cell proliferation and organ size. Hippo pathway molecules such as macrophage-stimulating 1/2 (MST1/2) and large tumor suppressor 1/2 (LATS1/2) regulate a transcriptional coactivator, Yes-associated protein (YAP) [98,99]. YAP controls stem or progenitor cell proliferation in the mouse postnatal epidermis [100]. Furthermore, YAP functions in balancing growth and differentiation in the skin [101,102].

Akladios *et al.* proposed a novel interplay among HH, YAP, Rho-associated protein kinase (ROCK) and β -catenin in the control of skin homeostasis [103]. HH signaling induces YAP activation, and activated YAP in turn induces β -catenin activation. HH, YAP and β -catenin together induce GLI2 activation to regulate epidermis homeostasis. At the same time, HH signaling activates ROCK in the epidermis. HH signaling and activated ROCK regulate cell proliferation and actin remodeling in the dermis.

8.3. p53/p63

The tumor suppressor, p53 is expressed in the epidermal basal layer and also in the outer root sheath and matrix of the hair follicles. Its expression is increased during the transition from anagen to the regression phase of the hair cycle (catagen), suggesting its role in hair follicle involution [104]. In addition, we previously demonstrated that HH signaling enhances the ubiquitin-mediated degradation of p53 through GLI1 [105]. Therefore, it is possible that HH signaling regulates hair cycling through regulating p53 protein.

A homolog of p53, p63, has an essential role in development. Mice lacking *p63* show extensive defects in epidermal development and die at birth [106,107]. In epidermis, an antiapoptotic protein and GLI target gene product, B-cell lymphoma 2 (BCL2) [108,109], is expressed in basal keratinocytes and the outer root sheath cells of the hair follicle. Its expression is associated with undifferentiated cells having proliferative potential. On the other hand, suprabasal keratinocytes do not express BCL2 [110]. These results suggest that BCL2 has an important role in regulating keratinocyte proliferation for skin homeostasis. Chari *et al.* demonstrated crosstalk between $\Delta Np63\alpha$, an isoform of p63 that is a crucial regulator of epidermal development, and HH signaling in keratinocytes [111]. HH signaling activation inhibits keratinocyte differentiation via GLI1-mediated upregulation of BCL2. At the same time, HH signaling activation results in $\Delta Np63\alpha$ expression. Upregulated p63 then activates transcription in keratinocytes of a negative regulator of HH signaling, SUFU. *In vivo* analysis indicates that SUFU is also a negative regulator of the Wnt signaling pathway [112]. Overall, these results suggest that the HH- $\Delta Np63\alpha$ axis regulates keratinocyte fate determination (proliferation or differentiation) for skin homeostasis.

9. Aberrant HH Signaling Pathway Activation and BCC

BCCs are so named because of their histological resemblance to basal cells of the interfollicular epidermis and epidermal appendages, that is, the keratinocytes adjacent to the stroma [113,114]. Activation of the HH signaling pathway through various mechanisms has been observed in BCCs [5]. Below, we introduce the mechanisms of BCC formation via the HH signaling pathway.

Although in general, BCCs seem to have relatively stable genomes, 67% of BCCs exhibit loss of *PTCH1*, 5% exhibit loss of *SUFU* and 10% have activating mutations of *SMO* [32,115,116]. However, GLI mutations (*GLI1*, *GLI2* and *GLI3*) are not observed in BCC patients, although GLI overexpression is observed. In addition, *NRAS*, *KRAS*, *HRAS*, *BRAF* and *CTNNB1* are not known to carry mutations in BCC patients [115].

Based on the molecular genetics analysis of human BCCs, several studies have been performed using genetically modified mice in which the HH signaling pathway is constitutively activated. Constitutive or conditional overexpression of either GLI1 [117] or GLI2 [118] in keratinocytes can produce BCC-like lesions in the skin. Similarly, expression of mutant SMO carrying the activating mutations identified in human BCCs [32] also can produce murine BCCs. Furthermore, *Ptch1*^{+/-} mice develop BCCs, and those BCCs often exhibit a deletion of the wild-type copy of *Ptch1* as well as upregulation of HH signaling. Similarly, mice carrying one inactivated, mutant allele of the HH suppressor, *SUFU* are also susceptible to BCC development [119].

Although these results show that the HH signaling pathway has important roles in BCC formation, the actual cell of origin remains to be elucidated. X-ray-induced BCCs in *Ptch1*^{+/-} mice arise predominantly, and likely exclusively, from hair follicle bulge stem cells expressing keratin 15 (a bulge cell marker). Furthermore, upregulation of SMO expression is necessary for BCC formation in X-irradiated *Ptch1*^{+/-} mice [120]. Using an inducible mouse model enabling expression of a constitutively active SMO mutant (SMO-M2) [32] in the adult epidermis, HH pathway activation was found to reprogram adult interfollicular cells to an embryonic hair follicle progenitor fate.

Furthermore, HH pathway activation induces the activation of Wnt/ β -catenin signaling. Deletion of β -catenin in adult SMO-M2-expressing cells prevents reprogramming to an embryonic hair follicle progenitor fate and also prevents tumor initiation [121]. Recently, deletion of *Ptch1* in different cellular compartments revealed that tumors can arise from multiple hair follicle stem cells and from innervated GLI1-expressing progenitor cells in the sensory structure known as the touch dome. In contrast, tumors do not arise from interfollicular epidermal stem cells [122].

BCC-specific signaling crosstalk between the HH and other signaling pathways has been reported. Eberl *et al.* reported crosstalk between the HH and EGFR signaling pathways in BCCs [41]. Skin-specific SMO-M2-expressing transgenic mice develop BCC-like lesions. However, skin-specific knockout of EGFR in SMO-M2-expressing mice reduces the number and size of BCCs. Furthermore, cooperation of HH and EGFR signaling induces specific GLI target genes such as *FGF19*, *TGFA*, *CXCR4*, *SOX9* and *SOX2*. These genes are not induced by activation of the canonical HH signaling pathway alone. These results suggest that cooperation between HH and EGFR signaling is important for BCC development, which is mediated by HH-EGFR cooperation-responsive GLI target genes.

Findings from studies of HH signaling activation-mediated tumorigenesis have recently culminated in the USA Food and Drug Administration's approval of GDC-0449 (vismodegib) [123], an oral inhibitor of SMO, as a therapeutic for treating advanced BCC. However, some studies have reported the emergence of SMO inhibitor-resistant tumors [124,125]. It will be important to understand the mechanisms by which SMO inhibitor-resistant cancer cells emerge, and to find novel therapeutic targets for these tumors. Atwood *et al.* reported that atypical protein kinase Ci/ λ (aPKC-i/ λ) is a novel GLI1 target gene product, and a novel therapeutic target for SMO inhibitor-resistant BCC [126]. aPKC-i/ λ functions downstream of SMO to phosphorylate and activate GLI1, resulting in maximal DNA binding and transcriptional activation. Activated aPKC-i/ λ is upregulated in SMO inhibitor-resistant tumors, and targeting aPKC-i/ λ suppresses GLI1 activation and the growth of SMO inhibitor-resistant BCC cell lines. These results suggest that aPKC-i/ λ is a novel therapeutic target for SMO inhibitor-resistant BCC.

Deregulated HH signaling is also involved in other skin cancers, including melanoma, squamous cell carcinoma and Merkel cell tumors. For the roles of the HH signaling pathway in these tumors, please refer to a published review [127].

10. Conclusions

The HH signaling pathway is one of the most fundamental in epidermal development and epidermal stem cell maintenance. However, deregulated HH signaling induces BCC. Hence, it is important that the intensity of the HH signal is strictly regulated during skin generation and homeostasis. To achieve precise regulation of HH signaling intensity, negative regulators of HH signaling are necessary, as well as crosstalk between the HH and other signal transduction pathways such as those activated by Wnt and BMP. Recently, it has been reported that low HH signaling activity is important for lung homeostasis [128]. Therefore, it is possible that fine-tuning the intensity of a HH signal may be involved in the homeostasis of multiple organs, including the skin.

As described above, aberrant activation of HH signaling causes BCC formation. A tumor microenvironment would exhibit not only the HH pathway regulatory mechanisms that are common with skin development and homeostasis, but also cancer cell-specific regulatory mechanisms. Therefore, understanding the precise mechanisms of HH pathway regulation in the tumor microenvironment is important to advance new therapeutic strategies for SMO inhibitor-resistant BCC. Moreover, such knowledge may also help to provide new therapeutic strategies for other HH pathway-activated cancers.

433 **Acknowledgments:** We thank Nicholas Rufaut, PhD, from Edanz Group (www.edanzediting.com/ac) for
434 editing a draft of this manuscript.

435 **Author Contributions:** Yoshinori Abe and Nobuyuki Tanaka contributed equally to this work.

436 **Conflicts of Interest:** The authors declare no conflict of interest.

References

1. Koster, M. I.; Roop, D. R. Mechanisms Regulating Epithelial Stratification. *Annual Review of Cell and Developmental Biology* **2007**, *23*, 93–113, doi:10.1146/annurev.cellbio.23.090506.123357.
2. Fuchs, E. Scratching the surface of skin development. *Nature* **2007**, *445*, 834–842, doi:10.1038/nature05659.
3. Blanpain, C.; Fuchs, E. Epidermal homeostasis: a balancing act of stem cells in the skin. *Nature reviews. Molecular cell biology* **2009**, *10*, 207–17, doi:10.1038/nrm2636.
4. Schmidt-Ullrich, R.; Paus, R. Molecular principles of hair follicle induction and morphogenesis. *BioEssays* **2005**, *27*, 247–261, doi:10.1002/bies.20184.
5. Epstein, E. H. Basal cell carcinomas: attack of the hedgehog. *Nature reviews. Cancer* **2008**, *8*, 743–54, doi:10.1038/nrc2503.
6. Thayer, S. P.; di Magliano, M. P.; Heiser, P. W.; Nielsen, C. M.; Roberts, D. J.; Lauwers, G. Y.; Qi, Y. P.; Gysin, S.; Fernández-del Castillo, C.; Yajnik, V.; Antoniu, B.; McMahon, M.; Warshaw, A. L.; Hebrok, M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. *Nature* **2003**, *425*, 851–6, doi:10.1038/nature02009.
7. Ng, J. M. Y.; Curran, T. The Hedgehog's tale: developing strategies for targeting cancer. *Nature Reviews Cancer* **2011**, *11*, 493–501, doi:10.1038/nrc3079.
8. Brechbiel, J.; Miller-Moslin, K.; Adjei, A. a Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer. *Cancer treatment reviews* **2014**, *40*, 750–9, doi:10.1016/j.ctrv.2014.02.003.
9. Aberger, F.; Ruiz i Altaba, A. Context-dependent signal integration by the GLI code: The oncogenic load, pathways, modifiers and implications for cancer therapy. *Seminars in Cell & Developmental Biology* **2014**, *33*, 93–104, doi:10.1016/j.semcdb.2014.05.003.
10. Pak, E.; Segal, R. A. Hedgehog Signal Transduction: Key Players, Oncogenic Drivers, and Cancer Therapy. *Developmental cell* **2016**, *38*, 333–44, doi:10.1016/j.devcel.2016.07.026.
11. Rohatgi, R.; Milenkovic, L.; Scott, M. P. Patched1 Regulates Hedgehog Signaling at the Primary Cilium. *Science* **2007**, *317*, 372–376, doi:10.1126/science.1139740.
12. Lee, Y.; Kawagoe, R.; Sasai, K.; Li, Y.; Russell, H. R.; Curran, T.; McKinnon, P. J. Loss of suppressor-of-fused function promotes tumorigenesis. *Oncogene* **2007**, *26*, 6442–7, doi:10.1038/sj.onc.1210467.
13. Allen, B. L.; Tenzen, T.; McMahon, A. P. The Hedgehog-binding proteins Gas1 and Cdo cooperate to positively regulate Shh signaling during mouse development. *Genes and Development* **2007**, *21*, 1244–1257, doi:10.1101/gad.1543607.

- 470 14. Okada, A.; Charron, F.; Morin, S.; Shin, D. S.; Wong, K.; Fabre, P. J.; Tessier-Lavigne, M.;
471 McConnell, S. K. Boc is a receptor for sonic hedgehog in the guidance of commissural axons.
472 *Nature* **2006**, *444*, 369–373, doi:10.1038/nature05246.
- 473 15. Yang, C.; Chen, W.; Chen, Y.; Jiang, J. Smoothed transduces Hedgehog signal by forming a
474 complex with Evc/Evc2. *Cell Research* **2012**, *22*, 1593–1604, doi:10.1038/cr.2012.134.
- 475 16. Dorn, K. V.; Hughes, C. E.; Rohatgi, R. A Smoothed-Evc2 Complex Transduces the
476 Hedgehog Signal at Primary Cilia. *Developmental Cell* **2012**, *23*, 823–835,
477 doi:10.1016/j.devcel.2012.07.004.
- 478 17. Corbit, K. C.; Aanstad, P.; Singla, V.; Norman, A. R.; Stainier, D. Y. R.; Reiter, J. F. Vertebrate
479 Smoothed functions at the primary cilium. *Nature* **2005**, *437*, 1018–21,
480 doi:10.1038/nature04117.
- 481 18. Haycraft, C. J.; Banizs, B.; Aydin-Son, Y.; Zhang, Q.; Michaud, E. J.; Yoder, B. K. Gli2 and Gli3
482 localize to cilia and require the intraflagellar transport protein polaris for processing and
483 function. *PLoS genetics* **2005**, *1*, e53, doi:10.1371/journal.pgen.0010053.
- 484 19. Abe, Y.; Tanaka, N. The Hedgehog Signaling Networks in Lung Cancer: The Mechanisms
485 and Roles in Tumor Progression and Implications for Cancer Therapy. *BioMed Research*
486 *International* **2016**, *2016*, 1–11, doi:10.1155/2016/7969286.
- 487 20. Sasaki, H.; Nishizaki, Y.; Hui, C.; Nakafuku, M.; Kondoh, H. Regulation of Gli2 and Gli3
488 activities by an amino-terminal repression domain: implication of Gli2 and Gli3 as primary
489 mediators of Shh signaling. *Development (Cambridge, England)* **1999**, *126*, 3915–24.
- 490 21. Bai, C. B.; Auerbach, W.; Lee, J. S.; Stephen, D.; Joyner, A. L. Gli2, but not Gli1, is required for
491 initial Shh signaling and ectopic activation of the Shh pathway. *Development (Cambridge,*
492 *England)* **2002**, *129*, 4753–61.
- 493 22. Masuya, H.; Sagai, T.; Moriwaki, K.; Shiroishi, T. Multigenic control of the localization of the
494 zone of polarizing activity in limb morphogenesis in the mouse. *Developmental biology* **1997**,
495 *182*, 42–51, doi:10.1006/dbio.1996.8457.
- 496 23. Büscher, D.; Bosse, B.; Heymer, J.; Rüther, U. Evidence for genetic control of Sonic hedgehog
497 by Gli3 in mouse limb development. *Mechanisms of development* **1997**, *62*, 175–82,
498 doi:10.1016/S0925-4773(97)00656-4.
- 499 24. Ding, Q.; Motoyama, J.; Gasca, S.; Mo, R.; Sasaki, H.; Rossant, J.; Hui, C. C. Diminished Sonic
500 hedgehog signaling and lack of floor plate differentiation in Gli2 mutant mice. *Development*
501 *(Cambridge, England)* **1998**, *125*, 2533–43, doi:9636069.
- 502 25. Tukachinsky, H.; Lopez, L. V.; Salic, A. A mechanism for vertebrate Hedgehog signaling:
503 Recruitment to cilia and dissociation of SuFu-Gli protein complexes. *Journal of Cell Biology*
504 **2010**, *191*, 415–428, doi:10.1083/jcb.201004108.

- 505 26. Park, H. L.; Bai, C.; Platt, K. A.; Matise, M. P.; Beeghly, A.; Hui, C. c; Nakashima, M.; Joyner,
506 A. L. Mouse Gli1 mutants are viable but have defects in SHH signaling in combination with a
507 Gli2 mutation. *Development (Cambridge, England)* **2000**, *127*, 1593–605,
508 doi:10.1101/gad.10.16.2003.
- 509 27. Bai, C. B.; Joyner, a L. Gli1 can rescue the in vivo function of Gli2. *Development (Cambridge,*
510 *England)* **2001**, *128*, 5161–72.
- 511 28. Rubin, L. L.; de Sauvage, F. J. Targeting the Hedgehog pathway in cancer. *Nature reviews.*
512 *Drug discovery* **2006**, *5*, 1026–33, doi:10.1038/nrd2086.
- 513 29. Raffel, C.; Jenkins, R. B.; Frederick, L.; Hebrink, D.; Alderete, B.; Fults, D. W.; James, C. D.
514 Sporadic medulloblastomas contain PTCH mutations. *Cancer research* **1997**, *57*, 842–5.
- 515 30. Wolter, M.; Reifenberger, J.; Sommer, C.; Ruzicka, T.; Reifenberger, G. Mutations in the
516 human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic
517 basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central
518 nervous system. *Cancer research* **1997**, *57*, 2581–5.
- 519 31. Reifenberger, J.; Wolter, M.; Weber, R. G.; Megahed, M.; Ruzicka, T.; Lichter, P.; Reifenberger,
520 G. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive
521 neuroectodermal tumors of the central nervous system. *Cancer research* **1998**, *58*, 1798–803.
- 522 32. Xie, J.; Murone, M.; Luoh, S. M.; Ryan, A.; Gu, Q.; Zhang, C.; Bonifas, J. M.; Lam, C. W.;
523 Hynes, M.; Goddard, A.; Rosenthal, A.; Epstein, E. H.; de Sauvage, F. J. Activating
524 Smoothened mutations in sporadic basal-cell carcinoma. *Nature* **1998**, *391*, 90–2,
525 doi:10.1038/34201.
- 526 33. Taylor, M. D.; Liu, L.; Raffel, C.; Hui, C.; Mainprize, T. G.; Zhang, X.; Agatep, R.; Chiappa, S.;
527 Gao, L.; Lowrance, A.; Hao, A.; Goldstein, A. M.; Stavrou, T.; Scherer, S. W.; Dura, W. T.;
528 Wainwright, B.; Squire, J. a; Rutka, J. T.; Hogg, D. Mutations in SUFU predispose to
529 medulloblastoma. *Nature genetics* **2002**, *31*, 306–10, doi:10.1038/ng916.
- 530 34. Pandolfi, S.; Stecca, B. Cooperative integration between HEDGEHOG-GLI signalling and
531 other oncogenic pathways: implications for cancer therapy. *Expert reviews in molecular*
532 *medicine* **2015**, *17*, e5, doi:10.1017/erm.2015.3.
- 533 35. Aberger, F.; Ruiz i Altaba, A. Context-dependent signal integration by the GLI code: The
534 oncogenic load, pathways, modifiers and implications for cancer therapy. *Seminars in Cell and*
535 *Developmental Biology* **2014**, *33*, 93–104, doi:10.1016/j.semcdb.2014.05.003.
- 536 36. Huelsken, J.; Vogel, R.; Erdmann, B.; Cotsarelis, G.; Birchmeier, W. β -Catenin Controls Hair
537 Follicle Morphogenesis and Stem Cell Differentiation in the Skin. *Cell* **2001**, *105*, 533–545,
538 doi:10.1016/S0092-8674(01)00336-1.

- 539 37. Suzuki, K.; Yamaguchi, Y.; Villacorte, M.; Mihara, K.; Akiyama, M.; Shimizu, H.; Taketo, M.
540 M.; Nakagata, N.; Tsukiyama, T.; Yamaguchi, T. P.; Birchmeier, W.; Kato, S.; Yamada, G.
541 Embryonic hair follicle fate change by augmented -catenin through Shh and Bmp signaling.
542 *Development* **2009**, *136*, 367–372, doi:10.1242/dev.021295.
- 543 38. Gat, U.; DasGupta, R.; Degenstein, L.; Fuchs, E. De Novo hair follicle morphogenesis and hair
544 tumors in mice expressing a truncated beta-catenin in skin. *Cell* **1998**, *95*, 605–14,
545 doi:10.1016/S0092-8674(00)81631-1.
- 546 39. Silva-Vargas, V.; Lo Celso, C.; Giangreco, A.; Ofstad, T.; Prowse, D. M.; Braun, K. M.; Watt, F.
547 M. β -Catenin and Hedgehog Signal Strength Can Specify Number and Location of Hair
548 Follicles in Adult Epidermis without Recruitment of Bulge Stem Cells. *Developmental Cell*
549 **2005**, *9*, 121–131, doi:10.1016/j.devcel.2005.04.013.
- 550 40. Javelaud, D.; Pierrat, M.-J.; Mauviel, A. Crosstalk between TGF- β and hedgehog signaling in
551 cancer. *FEBS letters* **2012**, *586*, 2016–25, doi:10.1016/j.febslet.2012.05.011.
- 552 41. Eberl, M.; Klingler, S.; Mangelberger, D.; Loipetzberger, A.; Damhofer, H.; Zoidl, K.;
553 Schnidar, H.; Hache, H.; Bauer, H.-C.; Solca, F.; Hauser-Kronberger, C.; Ermilov, A. N.;
554 Verhaegen, M. E.; Bichakjian, C. K.; Dlugosz, A. a; Nietfeld, W.; Sibilia, M.; Lehrach, H.;
555 Wierling, C.; Aberger, F. Hedgehog-EGFR cooperation response genes determine the
556 oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells.
557 *EMBO Molecular Medicine* **2012**, *4*, 218–233, doi:10.1002/emmm.201100201.
- 558 42. Nolan-Stevaux, O.; Lau, J.; Truitt, M. L.; Chu, G. C.; Hebrok, M.; Fernández-Zapico, M. E.;
559 Hanahan, D. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic
560 pancreatic ducts and mediates PDAC cell survival and transformation. *Genes & development*
561 **2009**, *23*, 24–36, doi:10.1101/gad.1753809.
- 562 43. Mazumdar, T.; DeVecchio, J.; Agyeman, A.; Shi, T.; Houghton, J. A. The GLI genes as the
563 molecular switch in disrupting Hedgehog signaling in colon cancer. *Oncotarget* **2011**, *2*, 638–
564 45.
- 565 44. Wang, Y.; Ding, Q.; Yen, C.-J.; Xia, W.; Izzo, J. G.; Lang, J.-Y.; Li, C.-W.; Hsu, J. L.; Miller, S. A.;
566 Wang, X.; Lee, D.-F.; Hsu, J.-M.; Huo, L.; Labaff, A. M.; Liu, D.; Huang, T.-H.; Lai, C.-C.; Tsai,
567 F.-J.; Chang, W.-C.; Chen, C.-H.; Wu, T.-T.; Buttar, N. S.; Wang, K. K.; Wu, Y.; Wang, H.;
568 Ajani, J.; Hung, M.-C. The crosstalk of mTOR/S6K1 and Hedgehog pathways. *Cancer cell* **2012**,
569 *21*, 374–87, doi:10.1016/j.ccr.2011.12.028.
- 570 45. Androutsellis-Theotokis, A.; Leker, R. R.; Soldner, F.; Hoepfner, D. J.; Ravin, R.; Poser, S. W.;
571 Rueger, M. a; Bae, S.-K.; Kittappa, R.; McKay, R. D. G. Notch signalling regulates stem cell
572 numbers in vitro and in vivo. *Nature* **2006**, *442*, 823–6, doi:10.1038/nature04940.
- 573 46. Mikkola, M. L. Genetic basis of skin appendage development. *Seminars in Cell and*
574 *Developmental Biology* **2007**, *18*, 225–236.

- 575 47. Motoyama, J.; Takabatake, T.; Takeshima, K.; Hui, C. Ptch2, a second mouse Patched gene is
576 co-expressed with Sonic hedgehog. *Nature genetics* **1998**, *18*, 104–6, doi:10.1038/ng0298-104.
- 577 48. Paus, R.; Müller-Röver, S.; Van Der Veen, C.; Maurer, M.; Eichmüller, S.; Ling, G.; Hofmann,
578 U.; Foitzik, K.; Mecklenburg, L.; Handjiski, B. A comprehensive guide for the recognition and
579 classification of distinct stages of hair follicle morphogenesis. *Journal of Investigative*
580 *Dermatology* **1999**, *113*, 523–532.
- 581 49. Forni, M. F.; Trombetta-Lima, M.; Sogayar, M. C. Stem cells in embryonic skin development.
582 *Biological research* **2012**, *45*, 215–22, doi:10.4067/S0716-97602012000300003.
- 583 50. St-Jacques, B.; Dassule, H. R.; Karavanova, I.; Botchkarev, V. A.; Li, J.; Danielian, P. S.;
584 McMahon, J. A.; Lewis, P. M.; Paus, R.; McMahon, A. P. Sonic hedgehog signaling is essential
585 for hair development. *Current Biology* **1998**, *8*, 1058–68, doi:10.1038/ng0298-104.
- 586 51. Chiang, C.; Swan, R. Z.; Grachtchouk, M.; Bolinger, M.; Litingtung, Y.; Robertson, E. K.;
587 Cooper, M. K.; Gaffield, W.; Westphal, H.; Beachy, P. a; Dlugosz, a a Essential role for Sonic
588 hedgehog during hair follicle morphogenesis. *Developmental biology* **1999**, *205*, 1–9,
589 doi:10.1006/dbio.1998.9103.
- 590 52. Mill, P. Sonic hedgehog-dependent activation of Gli2 is essential for embryonic hair follicle
591 development. *Genes & Development* **2003**, *17*, 282–294, doi:10.1101/gad.1038103.
- 592 53. Woo, W.-M.; Zhen, H. H.; Oro, A. E. Shh maintains dermal papilla identity and hair
593 morphogenesis via a Noggin-Shh regulatory loop. *Genes & development* **2012**, *26*, 1235–46,
594 doi:10.1101/gad.187401.112.
- 595 54. Biernaskie, J.; Paris, M.; Morozova, O.; Fagan, B. M.; Marra, M.; Pevny, L.; Miller, F. D. SKPs
596 Derive from Hair Follicle Precursors and Exhibit Properties of Adult Dermal Stem Cells. *Cell*
597 *Stem Cell* **2009**, *5*, 610–623, doi:10.1016/j.stem.2009.10.019.
- 598 55. Driskell, R. R.; Giangreco, A.; Jensen, K. B.; Mulder, K. W.; Watt, F. M. Sox2-positive dermal
599 papilla cells specify hair follicle type in mammalian epidermis. *Development (Cambridge,*
600 *England)* **2009**, *136*, 2815–23, doi:10.1242/dev.038620.
- 601 56. Chen, Y.; Struhl, G. Dual roles for patched in sequestering and transducing Hedgehog. *Cell*
602 **1996**, *87*, 553–563, doi:10.1016/S0092-8674(00)81374-4.
- 603 57. Adolphe, C.; Hetherington, R.; Ellis, T.; Wainwright, B. Patched1 functions as a gatekeeper by
604 promoting cell cycle progression. *Cancer research* **2006**, *66*, 2081–8,
605 doi:10.1158/0008-5472.CAN-05-2146.
- 606 58. Nieuwenhuis, E.; Motoyama, J.; Barnfield, P. C.; Yoshikawa, Y.; Zhang, X.; Mo, R.;
607 Crackower, M. A.; Hui, C. -c. Mice with a Targeted Mutation of Patched2 Are Viable but
608 Develop Alopecia and Epidermal Hyperplasia. *Molecular and Cellular Biology* **2006**, *26*, 6609–
609 6622, doi:10.1128/MCB.00295-06.

59. Adolphe, C.; Nieuwenhuis, E.; Villani, R.; Li, Z. J.; Kaur, P.; Hui, C.; Wainwright, B. J. Patched 1 and Patched 2 Redundancy Has a Key Role in Regulating Epidermal Differentiation. *Journal of Investigative Dermatology* **2014**, *134*, 1981–1990, doi:10.1038/jid.2014.63.
60. Mill, P.; Mo, R.; Hu, M. C.; Dagnino, L.; Rosenblum, N. D.; Hui, C.-C. Shh controls epithelial proliferation via independent pathways that converge on N-Myc. *Developmental cell* **2005**, *9*, 293–303, doi:10.1016/j.devcel.2005.05.009.
61. Adolphe, C.; Junker, J. P.; Lyubimova, A.; van Oudenaarden, A.; Wainwright, B. Patched Receptors Sense, Interpret, and Establish an Epidermal Hedgehog Signaling Gradient. *Journal of Investigative Dermatology* **2017**, *137*, 179–186, doi:10.1016/j.jid.2016.06.632.
62. Clevers, H. Wnt/beta-catenin signaling in development and disease. *Cell* **2006**, *127*, 469–80, doi:10.1016/j.cell.2006.10.018.
63. Van Camp, J. K.; Beckers, S.; Zegers, D.; Van Hul, W. Wnt Signaling and the Control of Human Stem Cell Fate. *Stem Cell Reviews and Reports* **2014**, *10*, 207–229.
64. Fuchs, E.; Merrill, B. J.; Jamora, C.; Dasgupta, R. At the Roots of a Never-Ending Cycle. *Developmental Cell* **2001**, *1*, 13–25.
65. Widelitz, R. B. Wnt signaling in skin organogenesis. *Organogenesis* **2008**, *4*, 123–133, doi:10.4161/org.4.2.5859.
66. Reddy, S.; Andl, T.; Bagasra, A.; Lu, M. M.; Epstein, D. J.; Morrissey, E. E.; Millar, S. E. Characterization of Wnt gene expression in developing and postnatal hair follicles and identification of Wnt5a as a target of Sonic hedgehog in hair follicle morphogenesis. *Mechanisms of Development* **2001**, *107*, 69–82, doi:10.1016/S0925-4773(01)00452-X.
67. Kwack, M. H.; Kim, M. K.; Kim, J. C.; Sung, Y. K. Wnt5a attenuates Wnt/ β -catenin signalling in human dermal papilla cells. *Experimental Dermatology* **2013**, *22*, 229–231, doi:10.1111/exd.12101.
68. Jamora, C.; DasGupta, R.; Kocieniewski, P.; Fuchs, E. Links between signal transduction, transcription and adhesion in epithelial bud development. *Nature* **2003**, *422*, 317–322, doi:10.1038/nature01458.
69. Rendl, M.; Polak, L.; Fuchs, E. BMP signaling in dermal papilla cells is required for their hair follicle-inductive properties. *Genes and Development* **2008**, *22*, 543–557, doi:10.1101/gad.1614408.
70. Millar, S. E. Molecular mechanisms regulating hair follicle development. *The Journal of investigative dermatology* **2002**, *118*, 216–25, doi:10.1046/j.0022-202x.2001.01670.x.
71. Mikkola, M. L.; Millar, S. E. The mammary bud as a skin appendage: Unique and shared aspects of development. *Journal of Mammary Gland Biology and Neoplasia* **2006**, *11*, 187–203, doi:10.1007/s10911-006-9029-x.

- 645 72. McMahon, A. P.; Paus, R. Noggin is a mesenchymally derived stimulator of hair-follicle
646 induction. *Nature cell biology* **1999**, *1*, 158–164, doi:10.1038/11078.
- 647 73. Irrthum, A.; Devriendt, K.; Chitayat, D.; Matthijs, G.; Glade, C.; Steijlen, P. M.; Fryns, J.-P.;
648 Van Steensel, M. A. M.; Vikkula, M. Mutations in the Transcription Factor Gene SOX18
649 Underlie Recessive and Dominant Forms of Hypotrichosis-Lymphedema-Telangiectasia. *The*
650 *American Journal of Human Genetics* **2003**, *72*, 1470–1478, doi:10.1086/375614.
- 651 74. Pennisi, D.; Bowles, J.; Nagy, A.; Muscat, G.; Koopman, P. Mice null for sox18 are viable and
652 display a mild coat defect. *Molecular and cellular biology* **2000**, *20*, 9331–9336,
653 doi:10.1128/MCB.20.24.9331-9336.2000.Updated.
- 654 75. Headon, D. J.; Overbeek, P. a Involvement of a novel Tnf receptor homologue in hair follicle
655 induction. *Nature genetics* **1999**, *22*, 370–4, doi:10.1038/11943.
- 656 76. Aggarwal, B. B. Signalling pathways of the TNF superfamily: a double-edged sword. *Nature*
657 *Reviews Immunology* **2003**, *3*, 745–756, doi:10.1038/nri1184.
- 658 77. Kumar, A.; Eby, M. T.; Sinha, S.; Jasmin, A.; Chaudhary, P. M. The ectodermal dysplasia
659 receptor activates the nuclear factor-kappaB, JNK, and cell death pathways and binds to
660 ectodysplasin A. *The Journal of biological chemistry* **2001**, *276*, 2668–77,
661 doi:10.1074/jbc.M008356200.
- 662 78. Mikkola, M. L.; Pispä, J.; Pekkanen, M.; Paulin, L.; Nieminen, P.; Kere, J.; Thesleff, I.
663 Ectodysplasin, a protein required for epithelial morphogenesis, is a novel TNF homologue
664 and promotes cell-matrix adhesion. *Mechanisms of Development* **1999**, *88*, 133–146,
665 doi:10.1016/S0925-4773(99)00180-X.
- 666 79. Schmidt-Ullrich, R.; Tobin, D. J.; Lenhard, D.; Schneider, P.; Paus, R.; Scheidereit, C.
667 NF-kappaB transmits Eda A1/EdaR signalling to activate Shh and cyclin D1 expression, and
668 controls post-initiation hair placode down growth. *Development (Cambridge, England)* **2006**,
669 *133*, 1045–57, doi:10.1242/dev.02278.
- 670 80. Dai, X.; Segre, J. A. Transcriptional control of epidermal specification and differentiation.
671 *Current Opinion in Genetics and Development* **2004**, *14*, 485–491.
- 672 81. Fuchs, E.; Byrne, C. The epidermis: rising to the surface. *Current Opinion in Genetics and*
673 *Development* **1994**, *4*, 725–736, doi:10.1016/0959-437X(94)90140-X.
- 674 82. Simpson, C. L.; Patel, D. M.; Green, K. J. Deconstructing the skin: cytoarchitectural
675 determinants of epidermal morphogenesis. *Nature Reviews Molecular Cell Biology* **2011**, *12*,
676 565–580, doi:10.1038/nrm3175.
- 677 83. Blanpain, C.; Horsley, V.; Fuchs, E. Epithelial Stem Cells: Turning over New Leaves. *Cell*
678 **2007**, *128*, 445–458.

- 679 84. Cotsarelis, G.; Sun, T. T.; Lavker, R. M. Label-retaining cells reside in the bulge area of
680 pilosebaceous unit: Implications for follicular stem cells, hair cycle, and skin carcinogenesis.
681 *Cell* **1990**, *61*, 1329–1337, doi:10.1016/0092-8674(90)90696-C.
- 682 85. Braun, K. M.; Niemann, C.; Jensen, U. B.; Sundberg, J. P.; Silva-Vargas, V.; Watt, F. M.
683 Manipulation of stem cell proliferation and lineage commitment: visualisation of
684 label-retaining cells in wholemounts of mouse epidermis. *Development (Cambridge, England)*
685 **2003**, *130*, 5241–5255, doi:10.1242/dev.00703.
- 686 86. Blanpain, C.; Lowry, W. E.; Geoghegan, A.; Polak, L.; Fuchs, E. Self-renewal, multipotency,
687 and the existence of two cell populations within an epithelial stem cell niche. *Cell* **2004**, *118*,
688 635–648, doi:10.1016/j.cell.2004.08.012.
- 689 87. Trempus, C. S.; Morris, R. J.; Bortner, C. D.; Cotsarelis, G.; Faircloth, R. S.; Reece, J. M.;
690 Tennant, R. W. Enrichment for living murine keratinocytes from the hair follicle bulge with
691 the cell surface marker CD34. *Journal of Investigative Dermatology* **2003**, *120*, 501–511,
692 doi:10.1046/j.1523-1747.2003.12088.x.
- 693 88. Panteleyev, A. A.; Jahoda, C. A.; Christiano, A. M. Hair follicle predetermination. *Journal of cell*
694 *science* **2001**, *114*, 3419–31.
- 695 89. Barker, N.; van Es, J. H.; Jaks, V.; Kasper, M.; Snippert, H.; Toftgård, R.; Clevers, H. Very
696 long-term self-renewal of small intestine, colon, and hair follicles from cycling Lgr5+ve stem
697 cells. *Cold Spring Harbor symposia on quantitative biology* **2008**, *73*, 351–6,
698 doi:10.1101/sqb.2008.72.003.
- 699 90. Wang, L. C.; Liu, Z. Y.; Gambardella, L.; Delacour, A.; Shapiro, R.; Yang, J.; Sizing, I.;
700 Rayhorn, P.; Garber, E. A.; Benjamin, C. D.; Williams, K. P.; Taylor, F. R.; Barrandon, Y.; Ling,
701 L.; Burkly, L. C. Conditional disruption of hedgehog signaling pathway defines its critical
702 role in hair development and regeneration. *Journal of Investigative Dermatology* **2000**, *114*, 901–
703 908, doi:10.1046/j.1523-1747.2000.00951.x.
- 704 91. Sato, N.; Leopold, P. L.; Crystal, R. G. Induction of the hair growth phase in postnatal mice by
705 localized transient expression of Sonic hedgehog. *Journal of Clinical Investigation* **1999**, *104*,
706 855–864, doi:10.1172/JCI7691.
- 707 92. Brownell, I.; Guevara, E.; Bai, C. B.; Loomis, C. A.; Joyner, A. L. Nerve-derived sonic
708 hedgehog defines a niche for hair follicle stem cells capable of becoming epidermal stem
709 cells. *Cell Stem Cell* **2011**, *8*, 552–565, doi:10.1016/j.stem.2011.02.021.
- 710 93. Hsu, Y. C.; Pasolli, H. A.; Fuchs, E. Dynamics between stem cells, niche, and progeny in the
711 hair follicle. *Cell* **2011**, *144*, 92–105, doi:10.1016/j.cell.2010.11.049.
- 712 94. Plikus, M. V.; Mayer, J. A.; de la Cruz, D.; Baker, R. E.; Maini, P. K.; Maxson, R.; Chuong,
713 C.-M. Cyclic dermal BMP signalling regulates stem cell activation during hair regeneration.
714 *Nature* **2008**, *451*, 340–344, doi:10.1038/nature06457.

- 715 95. Festa, E.; Fretz, J.; Berry, R.; Schmidt, B.; Rodeheffer, M.; Horowitz, M.; Horsley, V. Adipocyte
716 lineage cells contribute to the skin stem cell niche to drive hair cycling. *Cell* **2011**, *146*, 761–
717 771, doi:10.1016/j.cell.2011.07.019.
- 718 96. Keyes, B. E.; Segal, J. P.; Heller, E.; Lien, W.-H.; Chang, C.-Y.; Guo, X.; Oristian, D. S.; Zheng,
719 D.; Fuchs, E. Nfatc1 orchestrates aging in hair follicle stem cells. *Proceedings of the National*
720 *Academy of Sciences of the United States of America* **2013**, *110*, E4950-9,
721 doi:10.1073/pnas.1320301110.
- 722 97. Zhang, L. -j.; Guerrero-Juarez, C. F.; Hata, T.; Bapat, S. P.; Ramos, R.; Plikus, M. V.; Gallo, R. L.
723 Dermal adipocytes protect against invasive *Staphylococcus aureus* skin infection. *Science*
724 **2015**, *347*, 67–71, doi:10.1126/science.1260972.
- 725 98. Halder, G.; Johnson, R. L. Hippo signaling: growth control and beyond. *Development*
726 *(Cambridge, England)* **2011**, *138*, 9–22, doi:10.1242/dev.045500.
- 727 99. Zhao Li, L., Lei, Q. and Guan, K. L., B. The Hippo-YAP pathway in organ size control and
728 tumorigenesis: an updated version. *Genes & Development* **2010**, *24*, 862–874,
729 doi:10.1101/gad.1909210.The.
- 730 100. Akladios, B.; Mendoza-Reinoso, V.; Samuel, M. S.; Hardeman, E. C.; Khosrotehrani, K.; Key,
731 B.; Beverdam, A. Epidermal YAP2-5SA-ΔC Drives β-Catenin Activation to Promote
732 Keratinocyte Proliferation in Mouse Skin In Vivo. *Journal of Investigative Dermatology* **2017**,
733 *137*, 716–726, doi:10.1016/j.jid.2016.10.029.
- 734 101. Schlegelmilch, K.; Mohseni, M.; Kirak, O.; Pruszek, J.; Rodriguez, J. R.; Zhou, D.; Kreger, B. T.;
735 Vasioukhin, V.; Avruch, J.; Brummelkamp, T. R.; Camargo, F. D. Yap1 acts downstream of
736 α-catenin to control epidermal proliferation. *Cell* **2011**, *144*, 782–95,
737 doi:10.1016/j.cell.2011.02.031.
- 738 102. Zhang, H.; Pasolli, H. A.; Fuchs, E. Yes-associated protein (YAP) transcriptional coactivator
739 functions in balancing growth and differentiation in skin. *Proceedings of the National Academy*
740 *of Sciences* **2011**, *108*, 2270–2275, doi:10.1073/pnas.1019603108.
- 741 103. Akladios, B.; Mendoza Reinoso, V.; Cain, J. E.; Wang, T.; Lambie, D. L.; Watkins, D. N.;
742 Beverdam, A. Positive regulatory interactions between YAP and Hedgehog signalling in skin
743 homeostasis and BCC development in mouse skin in vivo. *PloS one* **2017**, *12*, e0183178,
744 doi:10.1371/journal.pone.0183178.
- 745 104. Botchkarev, V. A.; Flores, E. R. p53/p63/p73 in the epidermis in health and disease. *Cold*
746 *Spring Harbor perspectives in medicine* **2014**, *4*, 466–472, doi:10.1101/cshperspect.a015248.
- 747 105. Abe, Y.; Oda-Sato, E.; Tobiume, K.; Kawauchi, K.; Taya, Y.; Okamoto, K.; Oren, M.; Tanaka,
748 N. Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2.
749 *Proceedings of the National Academy of Sciences of the United States of America* **2008**, *105*, 4838–43,
750 doi:10.1073/pnas.0712216105.

106. Mills, A. A.; Zheng, B.; Wang, X. J.; Vogel, H.; Roop, D. R.; Bradley, A. P63 Is a P53 Homologue Required for Limb and Epidermal Morphogenesis. *Nature* **1999**, *398*, 708–713, doi:10.1038/19531.
107. Yang, A.; Schweitzer, R.; Sun, D.; Kaghad, M.; Walker, N.; Bronson, R. T.; Tabin, C.; Sharpe, A.; Caput, D.; Crum, C.; McKeon, F. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. *Nature* **1999**, *398*, 714–718, doi:10.1038/19539.
108. Bigelow, R. L. H.; Chari, N. S.; Undén, A. B.; Spurgers, K. B.; Lee, S.; Roop, D. R.; Toftgård, R.; McDonnell, T. J. Transcriptional Regulation of bcl-2 Mediated by the Sonic Hedgehog Signaling Pathway through gli-1. *Journal of Biological Chemistry* **2004**, *279*, 1197–1205, doi:10.1074/jbc.M310589200.
109. Regl, G.; Kasper, M.; Schnidar, H.; Eichberger, T.; Neill, G. W.; Philpott, M. P.; Esterbauer, H.; Hauser-Kronberger, C.; Frischauf, A.-M.; Aberger, F. Activation of the BCL2 promoter in response to Hedgehog/GLI signal transduction is predominantly mediated by GLI2. *Cancer research* **2004**, *64*, 7724–31, doi:10.1158/0008-5472.CAN-04-1085.
110. Polakowska, R. R.; Piacentini, M.; Bartlett, R.; Goldsmith, L. A.; Haake, A. R. Apoptosis in human skin development: Morphogenesis, periderm, and stem cells. *Developmental Dynamics* **1994**, *199*, 176–188, doi:10.1002/aja.1001990303.
111. Chari, N. S.; Romano, R. A.; Koster, M. I.; Jaks, V.; Roop, D.; Flores, E. R.; Teglund, S.; Sinha, S.; Gruber, W.; Aberger, F.; Medeiros, L. J.; Toftgard, R.; McDonnell, T. J. Interaction between the TP63 and SHH pathways is an important determinant of epidermal homeostasis. *Cell Death and Differentiation* **2013**, *20*, 1080–1088, doi:10.1038/cdd.2013.41.
112. Taylor, M. D.; Zhang, X.; Liu, L.; Hui, C.-C.; Mainprize, T. G.; Scherer, S. W.; Wainwright, B.; Hogg, D.; Rutka, J. T. Failure of a medulloblastoma-derived mutant of SUFU to suppress WNT signaling. *Oncogene* **2004**, *23*, 4577–83, doi:10.1038/sj.onc.1207605.
113. Rubin, A. I.; Chen, E. H.; Ratner, D. Basal-Cell Carcinoma. *New England Journal of Medicine* **2005**, *353*, 2262–2269, doi:10.1056/NEJMra044151.
114. Donovan, J. Review of the hair follicle origin hypothesis for basal cell Carcinoma. *Dermatologic Surgery* **2009**, *35*, 1311–1323.
115. Reifengerger, J.; Wolter, M.; Knobbe, C. B.; K??hler, B.; Sch??nicke, A.; Scharw??chter, C.; Kumar, K.; Blaschke, B.; Ruzicka, T.; Reifengerger, G. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. *British Journal of Dermatology* **2005**, *152*, 43–51, doi:10.1111/j.1365-2133.2005.06353.x.
116. Khavari, P. a Modelling cancer in human skin tissue. *Nature Reviews Cancer* **2006**, *6*, 270–280, doi:10.1038/nrc1838.

- 785 117. Nilsson, M.; Undèn, A. B.; Krause, D.; Malmqwist, U.; Raza, K.; Zaphiropoulos, P. G.;
786 Toftgård, R. Induction of basal cell carcinomas and trichoepitheliomas in mice
787 overexpressing GLI-1. *Proceedings of the National Academy of Sciences of the United States of*
788 *America* **2000**, *97*, 3438–43, doi:10.1073/pnas.050467397.
- 789 118. Grachtchouk, M.; Mo, R.; Yu, S.; Zhang, X.; Sasaki, H.; Hui, C. C.; Dlugosz, a a Basal cell
790 carcinomas in mice overexpressing Gli2 in skin. *Nature genetics* **2000**, *24*, 216–7,
791 doi:10.1038/73417.
- 792 119. Svärd, J.; Heby-Henricson, K.; Henricson, K. H.; Persson-Lek, M.; Rozell, B.; Lauth, M.;
793 Bergström, A.; Ericson, J.; Toftgård, R.; Teglund, S. Genetic elimination of Suppressor of
794 fused reveals an essential repressor function in the mammalian Hedgehog signaling
795 pathway. *Developmental cell* **2006**, *10*, 187–97, doi:10.1016/j.devcel.2005.12.013.
- 796 120. Wang, G. Y.; Wang, J.; Mancianti, M. L.; Epstein, E. H. Basal cell carcinomas arise from hair
797 follicle stem cells in Ptch1+/- mice. *Cancer Cell* **2011**, *19*, 114–124, doi:10.1016/j.ccr.2010.11.007.
- 798 121. Youssef, K. K.; Lapouge, G.; Bouvrée, K.; Rorive, S.; Brohée, S.; Appelstein, O.; Larsimont,
799 J.-C.; Sukumaran, V.; Van de Sande, B.; Pucci, D.; Dekoninck, S.; Berthe, J.-V.; Aerts, S.;
800 Salmon, I.; del Marmol, V.; Blanpain, C. Adult interfollicular tumour-initiating cells are
801 reprogrammed into an embryonic hair follicle progenitor-like fate during basal cell
802 carcinoma initiation. *Nature cell biology* **2012**, *14*, 1282–94, doi:10.1038/ncb2628.
- 803 122. Peterson, S. C.; Eberl, M.; Vagnozzi, A. N.; Belkadi, A.; Veniaminova, N. A.; Verhaegen, M. E.;
804 Bichakjian, C. K.; Ward, N. L.; Dlugosz, A. A.; Wong, S. Y. Basal cell carcinoma preferentially
805 arises from stem cells within hair follicle and mechanosensory niches. *Cell Stem Cell* **2015**, *16*,
806 400–412, doi:10.1016/j.stem.2015.02.006.
- 807 123. Robarge, K. D.; Brunton, S. A.; Castanedo, G. M.; Cui, Y.; Dina, M. S.; Goldsmith, R.; Gould, S.
808 E.; Guichert, O.; Gunzner, J. L.; Halladay, J.; Jia, W.; Khojasteh, C.; Koehler, M. F. T.; Kotkow,
809 K.; La, H.; LaLonde, R. L.; Lau, K.; Lee, L.; Marshall, D.; Marsters, J. C.; Murray, L. J.; Qian, C.;
810 Rubin, L. L.; Salphati, L.; Stanley, M. S.; Stibbard, J. H. A.; Sutherlin, D. P.; Ubhayaker, S.;
811 Wang, S.; Wong, S.; Xie, M. GDC-0449-A potent inhibitor of the hedgehog pathway.
812 *Bioorganic and Medicinal Chemistry Letters* **2009**, *19*, 5576–5581, doi:10.1016/j.bmcl.2009.08.049.
- 813 124. Sharpe, H. J.; Pau, G.; Dijkgraaf, G. J.; Basset-Seguin, N.; Modrusan, Z.; Januario, T.; Tsui, V.;
814 Durham, A. B.; Dlugosz, A. A.; Haverty, P. M.; Bourgon, R.; Tang, J. Y.; Sarin, K. Y.; Dirix, L.;
815 Fisher, D. C.; Rudin, C. M.; Sofen, H.; Migden, M. R.; Yauch, R. L.; de Sauvage, F. J. Genomic
816 Analysis of Smoothed Inhibitor Resistance in Basal Cell Carcinoma. *Cancer Cell* **2015**, *27*,
817 327–341, doi:10.1016/j.ccell.2015.02.001.
- 818 125. Atwood, S. X.; Sarin, K. Y.; Li, J. R.; Yao, C. Y.; Urman, N. M.; Chang, A. L. S.; Tang, J. Y.; Oro,
819 A. E. Rolling the Genetic Dice: Neutral and Deleterious Smoothed Mutations in
820 Drug-Resistant Basal Cell Carcinoma. *The Journal of investigative dermatology* **2015**, *135*, 2138–
821 41, doi:10.1038/jid.2015.115.

- 822 126. Atwood, S. X.; Li, M.; Lee, A.; Tang, J. Y.; Oro, A. E. GLI activation by atypical protein kinase
823 C ι/λ regulates the growth of basal cell carcinomas. *Nature* **2013**, *494*, 484–8,
824 doi:10.1038/nature11889.
- 825 127. Li, C.; Chi, S.; Xie, J. Hedgehog signaling in skin cancers. *Cellular Signalling* **2011**, *23*, 1235–
826 1243, doi:10.1016/j.cellsig.2011.03.002.
- 827 128. Peng, T.; Frank, D. B.; Kadzik, R. S.; Morley, M. P.; Rathi, K. S.; Wang, T.; Zhou, S.; Cheng, L.;
828 Lu, M. M.; Morrissey, E. E. Hedgehog actively maintains adult lung quiescence and regulates
829 repair and regeneration. *Nature* **2015**, *526*, 578–82, doi:10.1038/nature14984.